Breaking Finance News

TRACON Pharmaceuticals Inc (NASDAQ:TCON) stock price target increased to $15.00, reported earlier today by BTIG Research

Only yesterday TRACON Pharmaceuticals Inc (NASDAQ:TCON) traded 4.40% lower at $6.59. TRACON Pharmaceuticals Inc’s 50-day average is $5.88 and its 200-day average is $6.21. With the last stock close up 9.07% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. 28,390 shares of the stock traded, down from ann average trading volume of 36,238.

BTIG Research bumped the estimated target of TRACON Pharmaceuticals Inc (NASDAQ:TCON) to $15, stating a possible upside of 1.28%,

Previously on 7/29/2015, ROTH Capital released a statement about TRACON Pharmaceuticals Inc(NASDAQ:TCON) upped the target price from $0.00 to $18.00 that suggested an upside of 0.00%.

See Graphic Below:

TRACON Pharmaceuticals Inc (NASDAQ:TCON)

TRACON Pharmaceuticals Inc has a one-year low of $4.00 and a one-year high of $18.35 . TCON’s total market value is presently $0.0.

Brief Synopsis About TRACON Pharmaceuticals Inc (NASDAQ:TCON)

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, and a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *